Emollients, urea-containing
Brand names: Aquadrate, Balneum Plus, Calmurid, Eucerin
Urea-containing emollients are leave-on moisturisers used for dry, scaling and hyperkeratotic skin conditions such as ichthyosis and chronic eczema.
ClinCalc Pro is rebuilding its dose data from primary open sources — the manufacturer SmPC (eMC), the WHO Model Formulary and other official references — under clinician review. This drug's structured dose is not yet published here. Confirm all doses against the product SmPC and your local formulary before prescribing.
Clinical monograph
How it works
Urea acts as a humectant that binds water in the stratum corneum and has keratolytic properties that soften and reduce thickened, scaly skin.
Prescribing in practice
- Urea can cause transient stinging or burning, particularly on fissured, inflamed or broken skin, so warn patients and avoid application to acutely inflamed areas.
- They are particularly useful where additional softening of thickened or scaly skin is needed beyond a plain emollient.
- Some products combine urea with other agents such as lactic acid; check the full formulation for additional cautions.
Monitoring
No laboratory monitoring is required; review skin condition, tolerability and any stinging on application.
Counselling the patient
- A brief stinging sensation may occur, especially on cracked skin, and usually settles with continued use.
- Apply regularly to keep the skin hydrated and softened.
- Avoid the eyes and apply to clean skin, ideally after washing.
Evidence & guidelines
Urea-containing emollients are well-established in dermatological practice for dry and hyperkeratotic skin, consistent with NICE emollient-based management of eczema.
Reference: BAD; NICE CKS Eczema; Confirm identity and dosing against the manufacturer SPC (eMC) and NICE. Verify against your local formulary and current prescribing references before prescribing. Monograph status: clinician-reviewed (2026-07-04).
Related
Curated clinical cross-links plus same-class fallbacks.
- Suspicious Pigmented Lesion — Melanoma Pathway · NICE NG14 2015 / BAD
- Cellulitis and Erysipelas · NICE NG141 2019 / CREST
- Psoriasis — Severity Assessment and Step-Up Therapy · NICE NG153 2019 / BAD
- Atopic Eczema — Assessment and Step-Up Therapy · NICE NG95 2023
- Urticaria and Angioedema · BSACI / EAACI Guidelines 2022
- Acne Vulgaris — Grading and Treatment · NICE NG198 2021 / BAD